Yotam Bar-On

Yotam Bar-On

Auto-generated profile, based on publicly available information

Yotam Bar-On

Department of Immunology, The Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa 3525422, Israel

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MHMagnus A. G. Hoffmann
Magnus A. G. Hoffmann
YBYotam Bar-On
Yotam Bar-On
Zhi YangZhi Yang
Zhi Yang
HGHarry B. Gristick
Harry B. Gristick
PGPriyanthi N. P. Gnanapragasam
Priyanthi N. P. Gnanapragasam
Pamela J BjorkmanPamela J Bjorkman
Pamela J Bjorkman
Significance: The ability of HIV-1 to rapidly develop resistance against various therapeutics remains a roadblock to finding a cure. Here we propose that nanoparticle-based therapeutics that mimic HIV-1 target cells by presenting clusters of CD4, the HIV-1 receptor, could prevent effective viral escape. We show that CD4 multimerization on the nanoparticle dramatically enhanced the neutralization potency and breadth compared with conventional CD4-based reagents that present only one or two copies of CD4. The CD4 nanoparticles neutralized a range of diverse HIV-1 strains, including patient isolates resistant to multiple broadly neutralizing antibodies. This work describes a new therapeutic direction that exploits the need of HIV-1 to bind CD4 on target cells, thus warranting further investigation for the potential development of a cure.

31 July 2024 in Molecular Therapy
Verified
Journal Article
Open access
RMRomila Moirangthem
Romila Moirangthem
SCSapir Cordela
Sapir Cordela
DKDina Khateeb
Dina Khateeb
BSBen Shor
Ben Shor
IKIvan Kosik
Ivan Kosik
YBYotam Bar-On
Yotam Bar-On
Targeting multiple viral proteins is pivotal for sustained suppression of highly mutable viruses. In recent years, broadly neutralizing antibodies that target the influenza virus hemagglutinin and neuraminidase glycoproteins have been developed, and antibody monotherapy has been tested in preclinical and clinical studies to treat or prevent influenza virus infection. However, the impact of dual neutralization of the hemagglutinin and neuraminidase on the course of infection, as well as its therapeutic potential, has not been thoroughly tested. For this purpose, we generated a bispecific antibody that neutralizes both the hemagglutinin and the neuraminidase of influenza viruses. We demonstrated that this bispecific antibody has a dual antiviral activity as it blocks infection and prevents the release of progeny viruses from the infected cells. We show that dual neutralization of the hemagglutinin and the neuraminidase by a bispecific antibody is advantageous over monoclonal antibody combination as it resulted an improved neutralization capacity and augmented the antibody effector functions. Notably, the bispecific antibody showed enhanced antiviral activity in influenza virus-infected mice, reduced mice mortality and limited the virus mutation profile upon antibody administration. Thus, dual neutralization of the hemagglutinin and neuraminidase could be effective in controlling influenza virus infection.

25 November 2021 in Rheumatology
Verified
Journal Article
Open access
PDF file
LILiat Iancovici
Liat Iancovici
DKDina Khateeb
Dina Khateeb
OHOfer Harel
Ofer Harel
RPRegina Peri
Regina Peri
GSGleb Slobodin
Gleb Slobodin
YBYotam Bar-On
Yotam Bar-On
Objectives: The mRNA-based COVID-19 vaccines are now employed globally and have shown high efficacy in preventing SARS-CoV-2 infection. However, less is known about the vaccine efficacy in immune-suppressed individuals. This study sought to explore whether humoral immunity to the COVID-19 vaccine BNT162b2 is altered in RA patients treated with Janus kinase inhibitors by analysing their antibodies titre, neutralization activity and B cell responses. Methods: We collected plasma samples from 12 RA patients who were treated with Janus kinase inhibitors and received two doses of the BNT162b2 vaccine, as well as 26 healthy individuals who were vaccinated with the same vaccine. We analysed the quantity of the anti-spike IgG and IgA antibodies that were elicited following the BNT162b2 vaccination, the plasma neutralization capacity and the responsiveness of the B-lymphocytes. We used ELISA to quantify the antibody titres, and a plasma neutralization assay was used to determine the virus neutralization capacity. Alteration in expression of the genes that are associated with B cell activation and the germinal centre response were analysed by quantitative PCR. Results: Reduced levels of anti-spike IgG antibodies and neutralization capacity were seen in the RA patients who were treated with JAK inhibitors in comparison with healthy individuals. Furthermore, B cell responsiveness to the SARS-CoV-2 spike protein was reduced in the RA patients. Conclusion: RA patients who are treated with JAK inhibitors show a suppressed humoral response following BNT162b2 vaccination, as revealed by the quantity and quality of the anti-spike antibodies.

12 January 2022 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DKDina Khateeb
Dina Khateeb
TGTslil Gabrieli
Tslil Gabrieli
BSBar Sofer
Bar Sofer
AHAdi Hattar
Adi Hattar
SCSapir Cordela
Sapir Cordela
YBYotam Bar-On
Yotam Bar-On
In-depth analysis of SARS-CoV-2 quasispecies is pivotal for a thorough understating of its evolution during infection. The recent deployment of COVID-19 vaccines, which elicit protective anti-spike neutralizing antibodies, has stressed the importance of uncovering and characterizing SARS-CoV-2 variants with mutated spike proteins. Sequencing databases have allowed to follow the spread of SARS-CoV-2 variants that are circulating in the human population, and several experimental platforms were developed to study these variants. However, less is known about the SARS-CoV-2 variants that are developed in the respiratory system of the infected individual. To gain further insight on SARS-CoV-2 mutagenesis during natural infection, we preformed single-genome sequencing of SARS-CoV-2 isolated from nose-throat swabs of infected individuals. Interestingly, intra-host SARS-CoV-2 variants with mutated S genes or N genes were detected in all individuals who were analyzed. These intra-host variants were present in low frequencies in the swab samples and were rarely documented in current sequencing databases. Further examination of representative spike variants identified by our analysis showed that these variants have impaired infectivity capacity and that the mutated variants showed varied sensitivity to neutralization by convalescent plasma and to plasma from vaccinated individuals. Notably, analysis of the plasma neutralization activity against these variants showed that the L1197I mutation at the S2 subunit of the spike can affect the plasma neutralization activity. Together, these results suggest that SARS-CoV-2 intra-host variants should be further analyzed for a more thorough characterization of potential circulating variants.

25 May 2025 in European Journal of Immunology
Verified
Journal Article
Open access
RMRomila Moirangthem
Romila Moirangthem
YBYotam Bar‐On
Yotam Bar‐On
The basic concepts of passive immunization and the potential of antibody therapy to confer immunity against infectious diseases were introduced already in the late 19th century. This approach was also later implemented to extensively treat and prevent infections, but with the development of effective vaccines, it became restricted to only a few medical conditions such as snake bites, neutralization of toxins, and prevention of rabies infection. This has dramatically changed in the last decade, as antibodies have been widely used in the clinic for the treatment of COVID‐19 and the prevention of respiratory syncytial virus (RSV) infections. A stepping‐stone for the progress in monoclonal antibody generation was the development of single‐cell antibody cloning techniques that made it possible to develop effective neutralizing antibodies against highly mutable viruses such as influenza virus and HIV‐1. Here, we review the use of passive immunotherapy in the clinic for treating and controlling SARS‐CoV‐2 and RSV infections. We further discuss key developments that have made it possible to use monoclonal antibodies against the highly mutable HIV‐1 and influenza virus and advanced clinical trials designed to evaluate the efficacy of such an approach. Finally, we present recent findings that demonstrate that passive immunization can elicit long‐term immunity in the host.

11 September 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
RKRaghad Khaleafi
Raghad Khaleafi
JZJelena Zeleznjak
Jelena Zeleznjak
SCSapir Cordela
Sapir Cordela
SDShani Drucker
Shani Drucker
TRTihana Lenac Rovis
Tihana Lenac Rovis
YBYotam Bar-On
Yotam Bar-On
In recent years, reoviruses have been of major interest in immunotherapy because of their oncolytic properties. Preclinical and clinical trials, in which reovirus was used for the treatment of melanoma and glioblastoma, have paved the way for future clinical use of reovirus. However, little is known about how reovirus infection affects the tumor microenvironment and immune response towards infected tumor cells. Studies have shown that reovirus can directly stimulate natural killer (NK) cells, but how reovirus affects cellular ligands on tumor cells, which are ultimately key to tumor recognition and elimination by NK cells, has not been investigated. We tested how reovirus infection affects the binding of the NK Group-2 member D (NKG2D) receptor, which is a dominant mediator of NK cell anti-tumor activity. Using models of human-derived melanoma and glioblastoma tumors, we demonstrated that NKG2D ligands are downregulated in tumor cells post-reovirus-infection due to the impaired translation of these ligands in reovirus-infected cells. Moreover, we showed that downregulation of NKG2D ligands significantly impaired the binding of NKG2D to infected tumor cells. We further demonstrated that reduced recognition of NKG2D ligands significantly alters NK cell anti-tumor cytotoxicity in human primary NK cells and in the NK cell line NK-92. Thus, this study provides novel insights into reovirus-host interactions and could lead to the development of novel reovirus-based therapeutics that enhance the anti-tumor immune response.